Cost minimization analysis of treatments for metastatic HER2-positive breast cancer in Peru: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injections

Cost minimization analysis of treatments for metastatic HER2-positive breast cancer in Peru: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injections

Saved in:

Bibliographic Details
Main Authors:	Miguel Figallo, María F. Delgado, Mauricio Gonzalez, Adrián Arenas
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554192/?tool=EBI
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery system
by: Chris Wynne, et al.
Published: (2025-06-01)

Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study
by: Junxiao Wang, et al.
Published: (2025-07-01)

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial
by: Nan Niu, et al.
Published: (2025-07-01)

Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer
by: Iris Otoya, et al.
Published: (2024-01-01)

Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
by: R. A. Murashko, et al.
Published: (2025-03-01)

Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine
by: Sila Oksuz, et al.
Published: (2025-04-01)

Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis
by: George W. Jr. Sledge, et al.
Published: (2025-08-01)

Effect of HER2 Ile655Val polymorphism on the response to trastuzumab treatment in HER2-positive breast cancer patients
by: Zohreh Gheibipour, et al.
Published: (2025-07-01)

Trastuzumab deruxtecan in patients with active brain metastases from HER2-positive/low metastatic breast cancer: a retrospective multicenter real-world study
by: Fangfang Duan, et al.
Published: (2025-07-01)

Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports
by: Yan Meng, et al.
Published: (2025-08-01)

Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget’s Disease to Trastuzumab Monotherapy
by: S. Wakabayashi, et al.
Published: (2012-01-01)

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01)

Notch and Hedgehog Signalling Axis Drive Senescence in HER2-Positive Breast Cancer Resistant to Trastuzumab
by: Asiye Büşra Boz Er, et al.
Published: (2024-12-01)

Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report
by: Hiromi Nagata, et al.
Published: (2020-01-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review
by: I. V. Kolyadina
Published: (2023-10-01)

Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience
by: Neda Yaghoubi, et al.
Published: (2025-05-01)

Hedgehog inhibitors exert anti-proliferation effects and synergistically interact with trastuzumab in HER2-positive gastric cancer models
by: Zixin Yang, et al.
Published: (2025-05-01)

TRACKING HER2 TRAFFICKING AND ORGANELLE CROSSTALK IN TRASTUZUMAB-DERUXTECAN–TREATED BREAST CANCER CELLS USING MULTIMODAL IMAGING
Published: (2025-08-01)

Evaluation of the Effect of Radiotherapy Timing on Toxicity in HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine During the Adjuvant Period
by: İlknur Deliktaş Onur, et al.
Published: (2025-04-01)

Experience of therapy of psoriasis patients with methotrexate in the form of subcutaneous and intramuscularly injections
by: N. V. Zilberberg, et al.
Published: (2021-12-01)

Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy
by: Jinmei Zhou, et al.
Published: (2025-05-01)

Target Points in Trastuzumab Resistance
by: Sahar Shojaei, et al.
Published: (2012-01-01)

Efficacy of Sound Touch Elastography in Assessing Subcutaneous Lipohypertrophy from Insulin Injections
by: Xu J, et al.
Published: (2024-11-01)

COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA
by: N. L. Pogudina, et al.
Published: (2017-08-01)

Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings
by: Koshiro Fukuda, et al.
Published: (2025-04-01)

Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy
by: Koichi Hayano, et al.
Published: (2020-09-01)

Anti-metastatic Profiles of Boesenbergia pandurata towards MCF-7/HER2 Cells
by: Hilyatul Fadliyah, et al.
Published: (2018-06-01)

Extensive subcutaneous emphysema treated with subcutaneous angiocatheters
by: Lena Carleton, et al.
Published: (2023-10-01)

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
by: Anas Hamad, et al.
Published: (2024-07-01)

Insulin Therapy to Control Hyperglycemia in Diabetic Patients With Ischemic Stroke: A Comparative of Intravenous and Subcutaneous Injection
by: Seyyed Mahdi Zia Ziabari, et al.
Published: (2025-03-01)

PHARMACOKINETICS OF AVERSECTIN С1 AND PRAZIQUANTEL IN DOG BLOOD AFTER A SINGLE SUBCUTANEOUS INJECTION OF AVERTEL
by: V. B. Yastreb, et al.
Published: (2016-05-01)

MINIMALLY INVASIVE SURGERY IN TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Yu. A. Gevorkyan, et al.
Published: (2020-06-01)

Fixed-dose combinations in the treatment of hypertension to increase adherence
by: T. E. Morozova, et al.
Published: (2020-12-01)

The prognostic significance of FOXP3 expression in patients with metastatic HER2-positive breast cancer
by: O.I. Vynnychenko, et al.
Published: (2024-12-01)

Cardiac function surveillance practices and outcomes in patients with HER2-positive breast cancer treated with trastuzumab: a retrospective cohort study across a safety-net and tertiary care setting
by: Le Huang, et al.
Published: (2025-08-01)

An overview of fixed-dose combinations of antihypertensive drugs in South Africa
by: Natalie Schellack, et al.
Published: (2014-07-01)

Comparative effectiveness of fixed combinations of various ramipril and hydrochlorothiazide doses
by: I. E. Chazova, et al.
Published: (2010-08-01)

DISSOLUTION PROFILE STUDIES FOR RAMIPRIL AND LERCANIDIPINE FIXED-DOSE COMBINATION
by: A. A. Shadrin, et al.
Published: (2019-01-01)

Discordance of HER2 between primary tumors and lymph node metastatic lesions in invasive breast cancer
by: Noviana Nugrohowati, et al.
Published: (2025-02-01)